Nurix Therapeutics reported a massive increase in revenue and a swing to profitability for the third quarter 2026, primarily driven by the closing of its global collaboration with Roche. The company transitioned its lead program, bexobrutideg, into Phase 3 development and strategically narrowed its pipeline to extend its cash runway into 2029.

Key Highlights

  • Recognized $653.2 million in license revenue from the Roche collaboration, resulting in a net income of $549.8 million for the quarter.
  • Ended the period with $1.1 billion in cash and marketable securities, providing a liquidity runway into the second half of 2029.
  • Dosed the first patient in the Phase 3 DAYBreak CLL-306 trial, a randomized study comparing bexobrutideg against pirtobrutinib in relapsed/refractory CLL/SLL.
  • Discontinued clinical development of NX-2127 (zelebrudomide) to prioritize the wholly owned oncology portfolio and bexobrutideg combinations.